Although Bcl-XL inhibition is obviously avoided in patients to bypass thrombocytopenia, we used early-generation and later-generation drugs in this study and found that for in vitro mechanistic and pre-clinical evaluation, they were functionally equivalent. The gene discussed is BCL2L1; the disease is Thrombocytopenia.